TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00769626

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Patients in the usual care group will receive advice and education to remain active and anticipate a favorable prognosis. Patients will also receive medication from the primary care provider consistent with current evidence-based guidelines(acetaminophen or non-steroidal anti-inflammatories). Consistent with current practice guidelines, patients will be instructed to return to the primary care provider if they are not satisfied with their progress after 4 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early Treatment
Description: Patients in the early treatment group will receive the usual care intervention (advice and education, and medication consistent with current evidence-based guidelines). Patients will also be referred to physical therapy for 4 sessions over a 3-week period. A standardized protocol will be used in physical therapy including spinal manipulation and trunk strengthening exercises. Patients will be instructed to return to the primary care provider if they are not satisfied with their progress after completion of the 4 sessions.
Study: NCT03970837

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK3196165 (Otilimab)
Description: GSK3196165 solution in vial/pre-filled syringe (PFS) was administered SC.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK3196165 (Otilimab)
Description: GSK3196165 solution in vial/pre-filled syringe (PFS) was administered SC.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK3196165 (Otilimab)
Description: GSK3196165 solution in vial/pre-filled syringe (PFS) was administered SC.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK3196165 (Otilimab)
Description: GSK3196165 solution in vial/pre-filled syringe (PFS) was administered SC.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: GSK3196165 (Otilimab)
Description: GSK3196165 solution in vial/pre-filled syringe (PFS) was administered SC.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: GSK3196165 (Otilimab)
Description: GSK3196165 solution in vial/pre-filled syringe (PFS) was administered SC.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: GSK3196165 (Otilimab)
Description: GSK3196165 solution in vial/pre-filled syringe (PFS) was administered SC.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: GSK3196165 (Otilimab)
Description: GSK3196165 solution in vial/pre-filled syringe (PFS) was administered SC.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tofacitinib
Description: Tofacitinib capsule (over encapsulated 5mg tablet) was administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tofacitinib
Description: Tofacitinib capsule (over encapsulated 5mg tablet) was administered orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tofacitinib
Description: Tofacitinib capsule (over encapsulated 5mg tablet) was administered orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tofacitinib
Description: Tofacitinib capsule (over encapsulated 5mg tablet) was administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching GSK3196165 and Tofacitinib was administered.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching GSK3196165 and Tofacitinib was administered.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching GSK3196165 and Tofacitinib was administered.
Study: NCT02283034

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard BLS
Description: Standard basic life support = chest compressions without any feedback device (manual resuscitation)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The CPREazy
Description: Feedback device - 3

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The CPR PRO APP
Description: Feedback device - 4

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The CardioPump
Description: Feedback devices - 5

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard BLS
Description: Chest compressions without CPR feedback device (manual resuscitation)
Study: NCT00735150

Intervention type: BEHAVIORAL
Intervention: questionnaire, interview
Description: You will be asked to make a one-time visit to MSKCC. At that research visit, you will be asked to complete a short questionnaire about your knowledge of various reproductive technologies relevant to individuals at hereditary risk. Then you will watch a short presentation about these reproductive technologies and complete a second brief questionnaire to assess your understanding of the presentation. Afterwards, you will meet with an interviewer one-on-one for about one hour, during which time you may share your thoughts and feelings about the use of these reproductive technologies.
Study: NCT04340518

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Scleral lens
Description: Scleral contact lenses, manufactured in rigid gas permeable fluorosilicone acrylate polymers and treated with plasma treatment prior to use.
Study: NCT00077974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SU011248
Description: 50-mg orally taken daily for 4 weeks and off treatment for 2 weeks until progression or unacceptable toxicity
Study: NCT00519727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 325568
Description: 4 arms of single dose s.c. injections: A 50 mg B 100 mg C 200 mg D 400 mg 4 arms of multi-dose: 3 i.v. infusions over 1 week followed by 5 weekly s.c. injections AA 50 mg BB 100 mg CC 200 mg DD 400 mg or EE 50 mg~Placebo: 0.9% Sodium Chloride
Study: NCT01996605

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: placebo will be administered spinally
Study: NCT00519727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 325568
Description: 4 arms of single dose s.c. injections: A 50 mg B 100 mg C 200 mg D 400 mg 4 arms of multi-dose: 3 i.v. infusions over 1 week followed by 5 weekly s.c. injections AA 50 mg BB 100 mg CC 200 mg DD 400 mg or EE 50 mg~Placebo: 0.9% Sodium Chloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 325568
Description: 4 arms of single dose s.c. injections: A 50 mg B 100 mg C 200 mg D 400 mg 4 arms of multi-dose: 3 i.v. infusions over 1 week followed by 5 weekly s.c. injections AA 50 mg BB 100 mg CC 200 mg DD 400 mg or EE 50 mg~Placebo: 0.9% Sodium Chloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 325568
Description: 4 arms of single dose s.c. injections: A 50 mg B 100 mg C 200 mg D 400 mg 4 arms of multi-dose: 3 i.v. infusions over 1 week followed by 5 weekly s.c. injections AA 50 mg BB 100 mg CC 200 mg DD 400 mg or EE 50 mg~Placebo: 0.9% Sodium Chloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 325568
Description: 4 arms of single dose s.c. injections: A 50 mg B 100 mg C 200 mg D 400 mg 4 arms of multi-dose: 3 i.v. infusions over 1 week followed by 5 weekly s.c. injections AA 50 mg BB 100 mg CC 200 mg DD 400 mg or EE 50 mg~Placebo: 0.9% Sodium Chloride
Study: NCT03970837

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching GSK3196165 and Tofacitinib was administered.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching GSK3196165 and Tofacitinib was administered.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching GSK3196165 and Tofacitinib was administered.
Study: NCT00770536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A1: AMG 386 10 mg/kg + Liposomal doxorubicin
Description: Liposomal doxorubicin 50 mg/m2 IV Q4W in combination with AMG 386 10 mg/kg IV QW

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A1: AMG 386 10 mg/kg + Liposomal doxorubicin
Description: Liposomal doxorubicin 50 mg/m2 IV Q4W in combination with AMG 386 10 mg/kg IV QW
Study: NCT00519727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 325568
Description: 4 arms of single dose s.c. injections: A 50 mg B 100 mg C 200 mg D 400 mg 4 arms of multi-dose: 3 i.v. infusions over 1 week followed by 5 weekly s.c. injections AA 50 mg BB 100 mg CC 200 mg DD 400 mg or EE 50 mg~Placebo: 0.9% Sodium Chloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 325568
Description: 4 arms of single dose s.c. injections: A 50 mg B 100 mg C 200 mg D 400 mg 4 arms of multi-dose: 3 i.v. infusions over 1 week followed by 5 weekly s.c. injections AA 50 mg BB 100 mg CC 200 mg DD 400 mg or EE 50 mg~Placebo: 0.9% Sodium Chloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 325568
Description: 4 arms of single dose s.c. injections: A 50 mg B 100 mg C 200 mg D 400 mg 4 arms of multi-dose: 3 i.v. infusions over 1 week followed by 5 weekly s.c. injections AA 50 mg BB 100 mg CC 200 mg DD 400 mg or EE 50 mg~Placebo: 0.9% Sodium Chloride
Study: NCT03978832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone
Description: Oral risperidone
Study: NCT02795039

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Single 5 mL intramuscular injection (slowly over 1-2 minutes) of Fulvestrant into the right buttock (upper outer quadrant)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fulvestrant
Description: Single 5 mL intramuscular injection (slowly over 1-2 minutes) of Faslodex® (Fulvestrant) into the right buttock (upper outer quadrant)
Study: NCT00503490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP-376 (Levofloxacin solution for Inhalation)
Description: 40, 80, 120mg RDD

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: BID
Study: NCT03569189

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Fat Diet
Description: Participants will consume a high fat diet for 7 days with 65% of energy from fat. The diet will also provide an energy excess at 150% of energy requirements.~Participants will be provided with all of their meals and snacks throughout the study.
Study: NCT00583219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum-A toxin
Description: A simple bladder catheterization in the office with a standard urinary catheter and instill the Botulinum-A toxin/DMSO solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimethyl sulfoxide (DMSO)
Description: Subjects received 50 cc of DMSO in an aqueous solution for intravesical instillation with botulinum-A toxin. Each cc contained 0.54 gm DMSO.
Study: NCT04372303

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Compassion Fatigue Resiliency Program (CFRP)
Description: The purpose of Compassion Fatigue Resiliency Program (CFRP) is to provide oncology-hematology nurses with knowledge and skills that will increase their level of resilience by helping them recognize compassion fatigue, cope with its consequences and work effectively.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Compassion Fatigue Resiliency Program (CFRP)
Description: The purpose of Compassion Fatigue Resiliency Program (CFRP) is to provide oncology-hematology nurses with knowledge and skills that will increase their level of resilience by helping them recognize compassion fatigue, cope with its consequences and work effectively.
Study: NCT02131766

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DiAs
Description: DiAs is the central component of our system. It is a standard cell phone running on an Android operating system. The cell phone has been changed to prevent from (1) using it as a phone or browser, (2) changing the volume (3) accidentally shutting it off. The cell phone runs an algorithm and is connected to work with the insulin pump and continuous glucose monitor to help keep the blood sugar in a desired range and help avoid hypoglycemia during the night.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sensor Augmented Pump Therapy
Description: Insulin pump plus CGM.
Study: NCT02128087

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Two-way SMS intervention
Description: Clients will receive a weekly two-way SMS, meaning that the clients in this group will receive the same message as in the one-way SMS study arm, but in addition will be asked how they feel. Clients are required to either press 1 or respond well or press 2 or write 'Unwell in response in the language of their choice within 48 hours. A missing response after 48 hours triggers a second SMS to remind the client to respond. If after 24 more hours the participant still does not respond or if at any point s/he responds unwell then the study coordinator will follow up with a call within 24 hours.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: One-way SMS intervention group
Description: Clients will receive a weekly one-way SMS message. There will be no prompt for any response.
Study: NCT00034814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talampanel
Description: Non-enzyme-inducing TLP 35mg TID
Study: NCT05206617

Intervention type: OTHER
Intervention: No intervention - pure observational study
Description: No intervention
Study: NCT03582722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orlistat
Description: Participants will be instructed to take one 60mg capsule of orlistat with each meal containing fat, up to three capsules daily, for six months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsule
Description: Participants will be instructed to take one placebo capsule to match 60mg of orlistat with each meal containing fat, up to three capsules daily, for six months.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multivitamin
Description: A multivitamin will be provided to be taken once daily, at bedtime.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Multivitamin
Description: A multivitamin will be provided to be taken once daily, at bedtime.
Study: NCT05073159

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Allocating head-of-bed position
Description: Patients would be randomized 1:1 to elevated head of bed (30-degrees or more) or flat (0-degree) position

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Allocating head-of-bed position
Description: Patients would be randomized 1:1 to elevated head of bed (30-degrees or more) or flat (0-degree) position
Study: NCT01188655

Intervention type: DRUG
Intervention: Enbrel
Description: The patients will be treated in accordance with the requirements of the labeling of Enbrel® in Austria. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.~To record complete dosing information, initial dose will be documented at baseline and any change will be documented with date, dose and reason at the subsequent visits.
Study: NCT04084132

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulmonary valve replacement
Description: Surgical implantation of an adult-sized (≥ 18 mm) homograft or Contegra graft as right ventricle-to-pulmonary artery conduit under cardiopulmonary bypass through a sternotomy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulmonary valve replacement
Description: Surgical implantation of an adult-sized (≥ 18 mm) homograft or Contegra graft as right ventricle-to-pulmonary artery conduit under cardiopulmonary bypass through a sternotomy.
Study: NCT03493867

Intervention type: DEVICE
Group type: OTHER
Intervention: Vitaliti
Description: Measurements recorded by the Vitaliti device will be compared to the recordings from the arterial catheter.
Study: NCT02263495

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 175mg/m2 + D5W 500mL MIV over 3hrs before gemcitabine administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin
Description: 1.0 mg/m2, 2-5min iv before gemcitabine (or miv with NS 100ml in max.)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: PG:1250mg/m2 + NS 100ml MIV over 30mins EG:1000mg/m2 + NS 100ml MIV over 30mins

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: PG:1250mg/m2 + NS 100ml MIV over 30mins EG:1000mg/m2 + NS 100ml MIV over 30mins
Study: NCT03648307

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sample
Description: Blood sample for Hb A1C and lipid profile, blood pressure and BMI

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sample
Description: Blood sample for Hb A1C and lipid profile, blood pressure and BMI
Study: NCT03546790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Marijuana
Description: Marijuana smoked via blunts with different cigar wrappers

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Marijuana
Description: Marijuana smoked via blunts with different cigar wrappers

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Marijuana
Description: Marijuana smoked via blunts with different cigar wrappers
Study: NCT03428685

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dydrogesterone Oral Tablet
Description: Oral dysdrogesteone 10mg tds will be prescribed from 12 - 36+6 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebos will be prescribed from 12 - 36+6 weeks.
Study: NCT03292952

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KP415 oral capsule
Description: Daily dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KP415 oral capsule
Description: Daily dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Daily dose
Study: NCT03809832

Intervention type: DIAGNOSTIC_TEST
Intervention: Microbiological sampling
Description: An microbiological sampling of the ventilator humidifier will be performed.
Study: NCT00034814

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Enzyme-inducing placebo TID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talampanel
Description: Enzyme-inducing Talampanel 35 mg TID
Study: NCT03882554

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PoNS Treatment
Description: PoNS Treatment will consist of three stages: an in-clinic training program, a home training program, and an extended home training program. During all stages of the study, subjects will complete three training sessions per day, morning, afternoon and evening, 6 days per week.~Daily Training Program: The same daily training program will be performed during all stages with the exception of the morning BAT session, which is not performed during stage 2 or 3:~Morning:~Warm Up Exercises without the PoNS Balance Training with PoNS Gait Training with PoNS Breathing and Awareness Training (BAT) with PoNS 3- to 4-hour break between morning and afternoon sessions~Afternoon:~Balance Training with PoNS Movement Control Training without PoNS Gait Training with PoNS~Evening:~Breathing and Awareness Training with PoNS To be performed at home during all stages
Study: NCT03827369

Intervention type: DIAGNOSTIC_TEST
Intervention: ICU patient
Description: Our study is to measure the coefficient of variation of the HCV of the radial arterial pulse among ICU patients with multiple organ failures (MOF). Patients admitted to Taoyuan General Hospital were recorded during the 6 months study.
Study: NCT00770536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A3: AMG 386 15mg/kg + Liposomal doxorubicin
Description: A3: AMG 386 15 mg/kg IV QW + Liposomal doxorubicin 50 mg/m2 IV Q4W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A3: AMG 386 15mg/kg + Liposomal doxorubicin
Description: A3: AMG 386 15 mg/kg IV QW + Liposomal doxorubicin 50 mg/m2 IV Q4W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B1: AMG 386 10 mg/kg + Topotecan
Description: B1: AMG 386 10 mg/kg IV QW + Topotecan 4 mg/m2 IV days 1, 8, 15, of a 28 day dosing schedule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B1: AMG 386 10 mg/kg + Topotecan
Description: B1: AMG 386 10 mg/kg IV QW + Topotecan 4 mg/m2 IV days 1, 8, 15, of a 28 day dosing schedule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B3: AMG 386 15mg/kg + Topotecan
Description: AMG 386 15mg/kg IV QW + Topotecan 4mg/m2 IV days 1, 8, 15 of a 28 day dosing schedule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B3: AMG 386 15mg/kg + Topotecan
Description: AMG 386 15mg/kg IV QW + Topotecan 4mg/m2 IV days 1, 8, 15 of a 28 day dosing schedule
Study: NCT05777161

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent Coached Exposure Therapy - Individualized
Description: Subject and parent begin by working with a therapist to create an individualized fear hierarchy consisting of situations and stimuli that produce anxiety for the child, gradually progressing from less anxiety to more anxiety.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavior Therapy
Description: Subjects will work with a therapist using anxiety management strategies to address thoughts, feelings, and behaviors.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent Coached Exposure Therapy - Group (removed from study)
Description: Subjects and parents will work in a group setting to receive exposure therapy consisting of situations and stimuli that produce anxiety for the child, gradually progressing from less anxiety to more anxiety.
Study: NCT01520974

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ProBiora3 mints
Description: Probiotic mint tablet taken once daily for 12 weeks containing ProBiora3, a combination of three known healthy bacteria

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Description: Mint tablet taken once daily for 12 weeks without the ProBiora3 combination of three known healthy bacteria
Study: NCT02031016

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: fentanyl bolus injections on an as needed base, NEXT TO the fentanyl bolus injections on predetermined times; before incision, at sternotomy, at aorta canulation and at opening of the pericardium.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: starting with 0.15 ug/IBW(kg)/min, next to fentanyl bolus injections (200-500 ug) on predetermined times; before incision, at sternotomy, at aorta canulation and at opening of the pericardium.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: fentanyl bolus injections on predetermined times; before incision, at sternotomy, at aorta canulation and at opening of the pericardium.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: fentanyl bolus injections on predetermined times; before incision, at sternotomy, at aorta canulation and at opening of the pericardium.
Study: NCT01034787

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-675,206
Description: Patients will receive CP-675,206 at 15 mg/kg administered intravenously on day 1 of ever 90 cycle for up to 4 cycles or until progression or intolerance of toxicity. Tumor assessments will be done ever 3 months. Additional scans will be done if clinically indicated.